搜尋
Akebia Therapeutics Inc
AKBA添加自選
1.220USD
0.0000.00%
收盤 07-24 16:00（美東）報價延遲15分鐘
326.84M總市值
虧損本益比TTM
關於 Akebia Therapeutics Inc 公司
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Akebia Therapeutics Inc簡介
公司代碼AKBA
公司名稱Akebia Therapeutics Inc
上市日期Mar 20, 2014
CEOButler (John P)
員工數量181
證券類型Ordinary Share
年結日Mar 20
公司地址245 First Street
城市CAMBRIDGE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編02142
電話16178712098
網址https://akebia.com/
公司代碼AKBA
上市日期Mar 20, 2014
CEOButler (John P)
Akebia Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.21M
-2.15%
Mr. Nicholas (Nik) Grund
Mr. Nicholas (Nik) Grund
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
330.72K
+50.21%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
200.50K
+17.81%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
161.73K
+22.07%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
160.93K
+22.18%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
133.38K
+26.77%
Dr. Steven C. Gilman, Ph.D.
Dr. Steven C. Gilman, Ph.D.
Independent Director
Independent Director
122.83K
+29.06%
Mr. Erik Ostrowski
Mr. Erik Ostrowski
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
49.35K
-113.52%
Dr. Steven K. Burke, M.D.
Dr. Steven K. Burke, M.D.
Senior Vice President - Research and Development, Chief Medical Officer
Senior Vice President - Research and Development, Chief Medical Officer
--
--
Ms. Leanne M. Zumwalt
Ms. Leanne M. Zumwalt
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.21M
-2.15%
Mr. Nicholas (Nik) Grund
Mr. Nicholas (Nik) Grund
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
330.72K
+50.21%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
200.50K
+17.81%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
161.73K
+22.07%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
160.93K
+22.18%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
133.38K
+26.77%
常見問題
Akebia Therapeutics Inc的前五大股東是誰？
Akebia Therapeutics Inc的前五大股東如下：Mr. John P. Butler
有多少機構持有Akebia Therapeutics Inc(AKBA)的股份？
截至2026Q1，共有351家機構持有Akebia Therapeutics Inc的股份，合計持有的股份價值約為125.97M，占公司總股份的46.96% 。與2025Q4相比，機構持股有所增加，增幅為-14935721.00。